Decline in hepatitis C treatment uptake could threaten Australia's elimination targets

July 30, 2018, University of New South Wales
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

There has been a decline in the uptake of life-saving treatments among people living with hepatitis C, according to new data released by the Kirby Institute at UNSW Sydney.

The data, released ahead of World Hepatitis Day on 28 July, shows that 58,280 people have begun hepatitis C therapy since highly-curative treatments were placed on the Pharmaceutical Benefits Scheme in March 2016, however, more than 170,000 people in Australia are still living with the virus.

"The number of people being treated each month has declined in 2018 to less than 1,500. Without urgent action, Australia is in danger of missing World Health Organisation targets of hepatitis C elimination by 2030," said Professor Greg Dore, who is head of the Viral Hepatitis and Clinical Research Program at the Kirby Institute. The Kirby Institute has been monitoring the uptake of direct-acting antiviral hepatitis C in Australia since March 2016.

"These new regimens provide a cure for the vast majority of people, with 12 weeks or less oral therapy that is generally well tolerated. But it's clear that many people are still not aware these treatments exist. We need an increase in community awareness and education campaigns, and continued development of treatment models for marginalised populations, to ensure that everyone in Australia living with hepatitis C can access these treatments," said Professor Dore.

Australia was one of first countries to offer hepatitis C treatments at minimal cost and without restrictions based on a patient's stage of liver disease or current injecting behaviours. In addition, treatments can be prescribed by general practitioners, removing the barrier of needing specialist care.

The Kirby Institute's REACH-C study collects data on how many people who begin hepatitis C therapy are being cured of the virus. Early results in over 3,000 people show a cure rate of 96%, with equally high rates across all models of care including specialist services, primary care, sexual and community health clinics, and drug and alcohol services.

"The REACH-C study clearly shows us that people can be treated with great success outside of the traditional model of the specialist liver clinic," said Associate Professor Gail Matthews, co-leader of the study. "For many people, avoiding the hospital outpatient setting is attractive, and these findings should encourage people living with hepatitis C to come forward and discuss how to access new treatments through their GP or other health care providers."

The new treatments represent a huge scientific advancement when compared to the previous interferon-based therapies. Recent Kirby Institute research has also shown that these treatments are safe and effective for on opioid substitution therapy or who are current injectors – the major population currently affected by hepatitis C in Australia.

"Australia is considered a world leader in hepatitis C elimination," said Professor Dore. "We have all the tools we need to eliminate the virus, but we need to increase our efforts to reach those remaining with C."

Explore further: From chronic to cured—could Australia be the first to eliminate hep C?

Related Stories

From chronic to cured—could Australia be the first to eliminate hep C?

July 28, 2017
Australia is on track to eliminate hepatitis C by 2026, a new report released by the Kirby Institute on World Hepatitis Day shows.

New research: High burden of hepatitis C among people who inject drugs

July 23, 2018
New research: High burden of hepatitis C among people who inject drugs highlights the urgent need for harm reduction and treatment strategies

Latest research shows Australia on track to cure hepatitis C

February 21, 2017
More Australians have been treated for hepatitis C in the past 12 months than the last decade combined, following the listing of a new generation therapy on the Pharmaceutical Benefits Scheme.

July 28 is World Hepatitis Day

July 27, 2018
(HealthDay)—July 28 is World Hepatitis Day, according to an announcement published in the July 20 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

New research supports the removal of drug use as a restriction to hepatitis C treatment

August 9, 2016
New, highly curative hepatitis C therapy is both safe and effective as a treatment option for people who inject drugs receiving opioid substitution therapy according to the results of a world-first clinical trial led by Professor ...

WHO targets for chronic hepatitis B will be cost-effective

July 27, 2018
(HealthDay)—Meeting World Health Organization (WHO) targets for chronic hepatitis B by 2030 will be cost-effective, according to a report published in the July issue of Health Affairs.

Recommended for you

New hope for cystic fibrosis

October 19, 2018
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis.

Bug guts shed light on Central America Chagas disease

October 18, 2018
In Central America, Chagas disease, or American trypanosomiasis, is spread by the "kissing bug" Triatoma dimidiata. By collecting DNA from the guts of these bugs, researchers reporting in PLOS Neglected Tropical Diseases ...

Rapid genomic sequencing of Lassa virus in Nigeria enabled real-time response to 2018 outbreak

October 18, 2018
Mounting a collaborative, real-time response to a Lassa fever outbreak in early 2018, doctors and scientists in Nigeria teamed up with researchers at Broad Institute of MIT and Harvard and colleagues to rapidly sequence the ...

Researchers cure drug-resistant infections without antibiotics

October 17, 2018
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria ...

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

How drug resistant TB evolved and spread globally

October 17, 2018
The most common form of Mycobacterium tuberculosis (TB) originated in Europe and spread to Asia, Africa and the Americas with European explorers and colonialists, reveals a new study led by UCL and the Norwegian Institute ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.